Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

TARS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +47.9% in FY2025

Bobak Azamian, M.D., Ph.D. is the CEO of Tarsus Pharmaceuticals and was paid $6.6M in FY2025 (Dec), down 16%.

Pay$100 in the stock at the end of FY21 → $364
CEO pay is from each Tarsus Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Bobak Azamian, M.D., Ph.D.FY2025
  2. 2Aziz MottiwalaFY2025
  3. 3Jeffrey FarrowFY2025
  4. 4Seshadri Neervannan, Ph.D.FY2025
  5. 5Bryan Wahl, M.D., J.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Tarsus Pharmaceuticals paid its 5 named executives $17.3M in total in FY2025 (Dec). CEO Bobak Azamian, M.D., Ph.D. was paid $6.6M of that.

Name
Bobak Azamian, M.D., Ph.D.President, Chief Executive Officer and Board Chairman
Aziz MottiwalaChief Commercial OfficerNot disclosed
Jeffrey FarrowChief Financial Officer and Chief Strategy Officer
Seshadri Neervannan, Ph.D.Chief Operating Officer
Bryan Wahl, M.D., J.D.General CounselNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Tarsus Pharmaceuticals names 16 peer companies for pay. Among Tarsus Pharmaceuticals and these peers, CEO pay was the lowest of 5 and total shareholder return was 2nd highest of 5.

5th highest of 5in Tarsus Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$6.6M$35.9M

2nd highest of 5in Tarsus Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$59$495

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Scott MorrisonDirector · 3 yr on the boardIndependentAudit (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Tarsus Pharmaceuticals COO pay fell 18% to $2.6M. The stock rose 48% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Tarsus Pharmaceuticals CFO pay fell 17% to $2.7M. The stock rose 48% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Tarsus Pharmaceuticals CEO pay fell 16% to $6.6M. The stock rose 48% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Tarsus Pharmaceuticals Division head pay fell 11% to $2.8M. The stock rose 48% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Tarsus Pharmaceuticals COO pay rose 83% to $3.2M. The stock rose 173% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Tarsus Pharmaceuticals CFO pay fell 19% to $3.2M. The stock rose 173% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Tarsus Pharmaceuticals CEO pay rose 152% to $7.9M. The stock rose 173% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Tarsus Pharmaceuticals CEO pay fell 20% to $3.1M. The stock rose 38% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KFeb 23, 2026FY2025
Proxy statementDEF 14AApr 28, 2025FY2024
Annual report10-KFeb 25, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data